Marc Miravitlles
#102,977
Most Influential Person Now
Researcher
Marc Miravitlles's AcademicInfluence.com Rankings
Marc Miravitllesbiology Degrees
Biology
#5257
World Rank
#7689
Historical Rank
Computational Biology
#75
World Rank
#75
Historical Rank
Cell Biology
#141
World Rank
#148
Historical Rank
Molecular Biology
#457
World Rank
#466
Historical Rank
Download Badge
Biology
Marc Miravitlles's Degrees
- Bachelors Biology University of Barcelona
- Masters Genetics University of Oxford
Similar Degrees You Can Earn
Why Is Marc Miravitlles Influential?
(Suggest an Edit or Addition)Marc Miravitlles's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. (2000) (756)
- Epidemiology and costs of chronic obstructive pulmonary disease (2006) (731)
- Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities (2009) (673)
- Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study (2004) (556)
- Chronic obstructive pulmonary disease (2012) (473)
- Outcomes for COPD pharmacological trials: from lung function to biomarkers (2008) (450)
- Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. (1999) (427)
- Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline (2017) (415)
- Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD (2003) (408)
- Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. (2009) (400)
- Symptom variability in patients with severe COPD: a pan-European cross-sectional study (2010) (377)
- Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. (2003) (335)
- Factors Associated with Increased Risk of Exacerbation and Hospital Admission in a Cohort of Ambulatory COPD Patients: A Multiple Logistic Regression Analysis (2000) (327)
- Determinants of underdiagnosis of COPD in national and international surveys. (2015) (310)
- Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. (2002) (303)
- What is asthma−COPD overlap syndrome? Towards a consensus definition from a round table discussion (2016) (282)
- Interpretation of quality of life scores from the St George's Respiratory Questionnaire (2002) (279)
- Costs of chronic bronchitis and COPD: a 1-year follow-up study. (2003) (279)
- Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable (2017) (278)
- Consensus document on the overlap phenotype COPD-asthma in COPD. (2012) (272)
- Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. (2001) (267)
- Estimated numbers and prevalence of PI*S and PI*Z alleles of α1-antitrypsin deficiency in European countries (2006) (259)
- Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns (2014) (240)
- Systemic inflammation in chronic obstructive pulmonary disease: a population-based study (2010) (238)
- Understanding the impact of symptoms on the burden of COPD (2017) (227)
- Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo (1999) (220)
- Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. (2017) (204)
- Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. (2013) (202)
- Clinical Phenotypes of COPD: Identication, Denition and Implications for Guidelines (2012) (199)
- European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency (2017) (198)
- Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial (2010) (196)
- Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. (1999) (191)
- An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. (2015) (190)
- Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. (1992) (188)
- Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice (2012) (186)
- Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997–2007 (2009) (180)
- Spanish Guideline for COPD (GesEPOC). Update 2014 (2014) (175)
- Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable (2012) (174)
- The asthma–chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges (2015) (166)
- The natural history of community-acquired pneumonia in COPD patients: a population database analysis. (2012) (162)
- The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK (2015) (161)
- Impact and prevention of severe exacerbations of COPD: a review of the evidence (2017) (157)
- Documento de consenso sobre el fenotipo mixto EPOC-asma en la EPOC (2012) (155)
- A review of national guidelines for management of COPD in Europe (2016) (154)
- Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study (2014) (153)
- Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. (2015) (149)
- Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. (2012) (148)
- Chronic obstructive pulmonary disease: the disease and its burden to society. (2006) (146)
- An official American Thoracic Society/European Respiratory Society statement: research questions in COPD (2015) (145)
- Patient's perception of exacerbations of COPD--the PERCEIVE study. (2006) (140)
- Spanish guideline for COPD (GesEPOC). Update 2014. (2014) (139)
- Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. (2013) (137)
- Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. (2001) (137)
- Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline (2017) (133)
- Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? (2002) (126)
- Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement (2012) (125)
- Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. (2006) (118)
- Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. (2012) (118)
- Diagnóstico y tratamiento del déficit de alfa-1-antitripsina (2006) (114)
- The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions (2018) (111)
- Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. (2015) (111)
- Guía española de la EPOC (GesEPOC). Actualización 2014 (2014) (110)
- An official American Thoracic Society/European Respiratory Society statement: research questions in COPD (2015) (109)
- [Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD]. (2012) (108)
- Chronic bronchial infection in COPD. Is there an infective phenotype? (2012) (108)
- Laboratory testing of individuals with severe α1-antitrypsin deficiency in three European centres (2010) (107)
- Multicomponent indices to predict survival in COPD: the COCOMICS study (2012) (107)
- Cough and sputum production as risk factors for poor outcomes in patients with COPD. (2011) (100)
- IgG subclass deficiencies associated with bronchiectasis. (1996) (99)
- Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica (2001) (99)
- Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain (2007) (97)
- Difficulties in differential diagnosis of COPD and asthma in primary care. (2012) (95)
- Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers. (2005) (93)
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges. (2020) (93)
- Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. (2016) (92)
- Use of spirometry and patterns of prescribing in COPD in primary care. (2007) (92)
- Predictors of Adverse Outcome in Patients Hospitalised for Exacerbation of Chronic Obstructive Pulmonary Disease (2012) (91)
- Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (2012) (90)
- Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? (2013) (90)
- Diferencias geográficas en la prevalencia de EPOC en España: relación con hábito tabáquico, tasas de mortalidad y otros determinantes (2010) (89)
- Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development (2007) (89)
- Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional (2004) (89)
- Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update (2017) (88)
- COPD symptoms in the morning: impact, evaluation and management (2013) (85)
- Bronchiectasis in COPD patients: more than a comorbidity? (2017) (85)
- Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis (2011) (84)
- A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC) (2013) (83)
- Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline (2020) (83)
- Prevalence and Determinants of COPD in Spain: EPISCAN II. (2020) (82)
- Fenotipos clínicos de la EPOC. Identificación, definición e implicaciones para las guías de tratamiento (2012) (81)
- Impairment of quality of life in women with chronic obstructive pulmonary disease. (2012) (81)
- Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. (2013) (79)
- Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study (2017) (79)
- Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach (2013) (77)
- Exacerbations, Hospital Admissions and Impaired Health Status in Chronic Obstructive Pulmonary Disease (2006) (75)
- Simple method for alpha1-antitrypsin deficiency screening by use of dried blood spot specimens. (2000) (75)
- Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results (2011) (75)
- Alpha-1 antitrypsin deficiency: outstanding questions and future directions (2018) (75)
- Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps (2019) (74)
- Results of a case-detection programme for α1-antitrypsin deficiency in COPD patients (2005) (74)
- Rapid screening for alpha1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease using dried blood specimens. (2002) (73)
- Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD (2009) (72)
- Algorithm for identification of asthma–COPD overlap: consensus between the Spanish COPD and asthma guidelines (2017) (72)
- Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD (2012) (72)
- Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease (2010) (70)
- Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura (2007) (69)
- Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. (2005) (69)
- [Attitudes toward the diagnosis of chronic obstructive pulmonary disease in primary care]. (2006) (68)
- Clinical phenotypes of Italian and Spanish patients with &agr;1-antitrypsin deficiency (2012) (67)
- Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease (2017) (66)
- Factors Associated with a Low Level of Physical Activity in Patients with Chronic Obstructive Pulmonary Disease (2014) (66)
- Factors determining the quality of life of patients with COPD in primary care (2007) (66)
- Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics (2006) (65)
- Beyond FEV 1 in COPD: a review of patient-reported outcomes and their measurement (2012) (65)
- Factors associated with depression and severe depression in patients with COPD. (2014) (65)
- Rare alpha-1-antitrypsin variants: are they really so rare? (2012) (64)
- Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique (2017) (64)
- Liver Fibrosis and Metabolic Alterations in Adults with Alpha1 Antitrypsin Deficiency Caused by the Pi*ZZ Mutation. (2019) (63)
- [Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): prevalence of chronic respiratory symptoms and airflow limitation]. (1999) (63)
- Is a previous diagnosis of asthma a reliable criterion for asthma–COPD overlap syndrome in a patient with COPD? (2015) (63)
- Socioeconomic Status and Health-Related Quality of Life of Patients with Chronic Obstructive Pulmonary Disease (2011) (63)
- Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. (2011) (62)
- Glutathione S-transferase P1 and lung function in patients with alpha1-antitrypsin deficiency and COPD. (2005) (62)
- El coste de la enfermedad pulmonar obstructiva crónica en España. Opciones para una optimización de recursos (2001) (61)
- Prevalence, Risk Factors and Diagnostic Accuracy of COPD Among Smokers in Primary Care (2015) (61)
- Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD (2009) (61)
- Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. (2014) (61)
- Pathophysiology of dyspnea in COPD (2017) (61)
- Diagnostic value of bronchoalveolar lavage in peripheral lung cancer. (1993) (60)
- Caregivers’ burden in patients with COPD (2015) (60)
- Geographic differences in clinical characteristics and management of COPD: the EPOCA study (2008) (60)
- Differences between physician and patient in the perception of symptoms and their severity in COPD. (2013) (60)
- Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare (2008) (59)
- Impact of Obesity on the Clinical Profile of a Population-Based Sample with Chronic Obstructive Pulmonary Disease (2014) (58)
- COPD management: role of symptom assessment in routine clinical practice (2013) (58)
- The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease (2021) (58)
- Estudio EPI-SCAN: resumen del protocolo de un estudio para estimar la prevalencia de EPOC en personas de 40 a 80 años en España (2009) (58)
- Infradiagnóstico de la enfermedad pulmonar obstructiva crónica en mujeres: cuantificación del problema, determinantes y propuestas de acción (2013) (58)
- Effects of whole body vibration training in patients with severe chronic obstructive pulmonary disease (2013) (57)
- Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey (2009) (57)
- Factors associated with changes in quality of life of COPD patients: a prospective study in primary care. (2013) (57)
- Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience. (1998) (57)
- Desarrollo y resultados de un programa de cribado de la EPOC en atención primaria. El proyecto PADOC (2000) (56)
- Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review (2016) (55)
- Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD. (2021) (55)
- Tratamiento de la bronquitis crónica y la EPOC en atención primaria (1999) (55)
- Frequency and characteristics of different clinical phenotypes of chronic obstructive pulmonary disease. (2015) (55)
- Th-2 signature in chronic airway diseases: towards the extinction of asthma−COPD overlap syndrome? (2017) (54)
- Treatment and quality of life in patients with chronic obstructive pulmonary disease (2002) (54)
- A simple algorithm for the identification of clinical COPD phenotypes (2017) (53)
- Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems (2014) (53)
- Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). (2017) (53)
- A study of adherence to antibiotic treatment in ambulatory respiratory infections. (2013) (53)
- Utilización de la espirometría en el diagnóstico y tratamiento de la EPOC en atención primaria (2006) (53)
- Datos epidemiológicos de EPOC en España (2007) (53)
- Incidence and significance of acid-fast bacilli in sputum smears at the end of antituberculous treatment. (1996) (53)
- Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis (2021) (53)
- [Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study]. (2004) (52)
- Improving physical activity in patients with COPD with urban walking circuits. (2013) (52)
- Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study (2017) (52)
- [Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors]. (2010) (51)
- Enfermedad pulmonar obstructiva crónica (2005) (51)
- The concept of control of COPD in clinical practice (2014) (51)
- Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide (2017) (51)
- Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease (2013) (50)
- Consenso sobre el solapamiento de asma y EPOC (ACO) entre la Guía española de la EPOC (GesEPOC) y la Guía Española para el Manejo del Asma (GEMA) (2017) (50)
- Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation (2016) (50)
- Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial (2013) (50)
- Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. (2013) (49)
- Factors associated with high healthcare resource utilisation among COPD patients. (2012) (49)
- Consensus on the Asthma–COPD Overlap (ACO) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA) (2017) (48)
- Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update. (2015) (48)
- Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study (2014) (48)
- The higher the number of daily doses of antibiotic treatment in lower respiratory tract infection the worse the compliance. (2008) (48)
- Estudio epidemiológico de la EPOC en España (IBERPOC): reclutamiento y trabajo de campo (1999) (47)
- Conocimientos de la población general sobre la enfermedad pulmonar obstructiva crónica y sus determinantes: situación actual y cambios recientes (2012) (47)
- [The EPI-SCAN survey to assess the prevalence of chronic obstructive pulmonary disease in Spanish 40-to-80-year-olds: protocol summary]. (2009) (47)
- Actualización sobre indicaciones de búsqueda activa de casos y tratamiento con alfa-1 antitripsina por vía intravenosa en pacientes con enfermedad pulmonar obstructiva crónica asociada a déficit de alfa-1 antitripsina (2015) (46)
- New horizons in early stage COPD--improving knowledge, detection and treatment. (2011) (46)
- Underdiagnosis of chronic obstructive pulmonary disease in women: quantification of the problem, determinants and proposed actions. (2013) (46)
- Adherence to inhaled therapies of COPD patients from seven Latin American countries: The LASSYC study (2017) (46)
- Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research – a consensus document from six scientific societies (2017) (45)
- Spirometrically-defined restrictive ventilatory defect: population variability and individual determinants. (2012) (45)
- The general public's knowledge of chronic obstructive pulmonary disease and its determinants: current situation and recent changes. (2012) (45)
- Validation of the COPD severity score for use in primary care: the NEREA study (2009) (45)
- Epidemiology of Chronic Obstructive Pulmonary Disease Exacerbations (2002) (44)
- Diagnosis of asthma–COPD overlap: the five commandments (2017) (44)
- Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. (2005) (44)
- Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting (2013) (44)
- COPD severity score as a predictor of failure in exacerbations of COPD. The ESFERA study. (2011) (43)
- ESTUDIO DEL CONTAGIO EN 3.071 CONTACTOS FAMILIARES DE ENFERMOS CON TUBERCULOSIS (1997) (43)
- Problemas con el diagnstico de la EPOC en atencin primaria (2006) (43)
- Influence of deficient alpha1-anti-trypsin phenotypes on clinical characteristics and severity of asthma in adults. (2002) (43)
- Factors Associated with Depression in COPD: A Multicenter Study (2016) (43)
- The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations. (2015) (42)
- What pulmonologists think about the asthma–COPD overlap syndrome (2015) (42)
- The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group (2019) (42)
- Clinical Outcomes and Cost Analysis of Exacerbations in Chronic Obstructive Pulmonary Disease (2013) (42)
- Prevalence and incidence of bronchiectasis in Catalonia, Spain: A population-based study. (2016) (42)
- Can cumulative tobacco consumption, FTND score, and carbon monoxide concentration in expired air be predictors of chronic obstructive pulmonary disease? (2004) (41)
- Variability of respiratory symptoms in severe COPD. (2012) (40)
- Mixed Th2 and non-Th2 inflammatory pattern in the asthma–COPD overlap: a network approach (2018) (40)
- Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT® studies (2009) (40)
- Guidelines for the Diagnosis and Management of α1-Antitrypsin Deficiency (2006) (40)
- Role of infection in exacerbations of chronic obstructive pulmonary disease (2015) (39)
- Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency; Comparison of the Characteristics of PISZ and PIZZ Individuals (2015) (39)
- Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics? (2017) (39)
- Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. (2017) (39)
- [Use of spirometry in the diagnosis and treatment of chronic obstructive pulmonary disease in primary care]. (2006) (39)
- Specific antibody response against the 23-valent pneumococcal vaccine in patients with alpha(1)-antitrypsin deficiency with and without bronchiectasis. (1999) (39)
- Prognostic assessment in COPD without lung function: the B-AE-D indices (2016) (39)
- Impact of Chronic Obstructive Pulmonary Disease on Activities of Daily Living: Results of the Multicenter EIME Study (2007) (39)
- Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. (2005) (38)
- Muscular Dysfunction in COPD: Systemic Effect or Deconditioning? (2013) (38)
- A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD (2016) (38)
- [Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement]. (2008) (38)
- Variabilidad en la realización de la espirometría y sus consecuencias en el tratamiento de la EPOC en Atención Primaria (2011) (38)
- Underdiagnosis of Chronic Obstructive Pulmonary Disease in Women: Quantification of the Problem, Determinants and Proposed Actions (2013) (38)
- Speed of Recovery from Acute Exacerbations of Chronic Obstructive Pulmonary Disease after Treatment with Antimicrobials (2003) (38)
- Variability in the performing of spirometry and its consequences in the treatment of COPD in primary care. (2011) (37)
- Tratamiento individualizado de la EPOC: una propuesta de cambio (2009) (37)
- Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey (2019) (37)
- Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study. (2020) (37)
- A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease (2017) (37)
- Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable (2012) (37)
- [Alpha-1 antitrypsin deficiency: diagnosis and treatment]. (2008) (37)
- Increased risk of tuberculosis transmission in families with microepidemics. (1997) (36)
- α1-antitrypsin deficiency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001 (2002) (36)
- Sex differences between women and men with COPD: A new analysis of the 3CIA study. (2020) (36)
- Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional (2004) (36)
- Validation of clinical control in COPD as a new tool for optimizing treatment (2018) (36)
- Tratamiento antimicrobiano de la agudización de la EPOC: Documento de Consenso 2007 (2008) (35)
- Alpha-1-antitrypsin and other proteinase inhibitors. (2012) (35)
- Cognitive status among patients with chronic obstructive pulmonary disease (2016) (35)
- Artificial intelligence and machine learning in respiratory medicine (2020) (35)
- GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort (2017) (35)
- THE EFFICACY OF MOXIFLOXACIN IN ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS: A SPANISH PHYSICIAN AND PATIENT EXPERIENCE (2001) (34)
- Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease (2015) (34)
- Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study (2016) (34)
- Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC). Versión 2017 (2017) (34)
- A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease (2015) (34)
- Palliative care and prognosis in COPD: a systematic review with a validation cohort (2017) (34)
- Characterization of specific immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23-valent pneumococcal vaccine in a healthy adult population: proposal for response criteria (1997) (34)
- Variability of Respiratory Symptoms in Severe COPD (2012) (34)
- Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. (2011) (34)
- Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics (2017) (34)
- Factors associated with hospital admission for exacerbation of chronic obstructive pulmonary disease. (2012) (33)
- Impacto de la EPOC en la vida diaria de los pacientes. Resultados del estudio multicéntrico EIME (2007) (33)
- Antibiotic prophylaxis in COPD: Why, when, and for whom? (2015) (33)
- An economic analysis of pharmacological treatment of COPD in Spain. (2009) (32)
- Corticoides inhalados en la EPOC por fenotipo en lugar de por gravedad. Argumentos a favor (2011) (32)
- No more equivalence trials for antibiotics in exacerbations of COPD, please. (2004) (32)
- Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis (2017) (32)
- Calidad y fuerza: el sistema GRADE para la formulación de recomendaciones en las guías de práctica clínica (2013) (32)
- Distribution and prognostic validity of the new GOLD grading classification. (2012) (31)
- Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence (2017) (31)
- Practical Guide to the Identification and Diagnosis of Asthma-COPD Overlap (ACO) (2019) (31)
- Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study (2009) (31)
- Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care (2004) (31)
- Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency (2007) (31)
- Empiric treatments impair the diagnostic yield of BAL in HIV-positive patients. (1997) (31)
- The concept of control in COPD: a new proposal for optimising therapy (2014) (31)
- The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency (2019) (31)
- “Correct Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease”: A Consensus Document (2015) (31)
- Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD (2021) (30)
- Effect of Various Antimicrobial Regimens on the Clinical Course of Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease in Primary Care (2004) (30)
- Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease. (2017) (30)
- The Experience of COPD Patients in Lockdown Due to the COVID-19 Pandemic (2020) (30)
- Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD (2007) (29)
- A new two-step algorithm for the treatment of COPD (2017) (29)
- [Guidelines for the diagnosis and management of alpha-1 antitrypsin deficiency]. (2006) (29)
- Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. (2018) (29)
- Triple Therapy in COPD: What We Know and What We Don't (2017) (28)
- GOLD en 2017: una visión desde la Guía Española de la EPOC (GesEPOC) (2017) (28)
- The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD (2015) (28)
- Atención médica según el nivel de riesgo y su adecuación a las recomendaciones de la guía española de la enfermedad pulmonar obstructiva crónica (EPOC) (GesEPOC): Estudio EPOCONSUL (2018) (28)
- Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study (2018) (28)
- Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial (2017) (28)
- Identification and molecular characterization of the new alpha-1-antitrypsin deficient allele PI Y barcelona (Asp256-->Val and Pro391-->His). Mutations in brief no. 174. Online. (1998) (28)
- Moxifloxacin in respiratory tract infections (2005) (28)
- The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis (2016) (28)
- Patient‐reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations (2018) (27)
- Actualización de las recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC (2004) (27)
- Russian guidelines for the management of COPD: algorithm of pharmacologic treatment (2018) (27)
- Practice and knowledge about diagnosis and treatment of alpha-1 antitrypsin deficiency in Spain and Portugal (2016) (27)
- Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency: Database Evaluation and Population Analysis. (2017) (27)
- Respiratory guidelines--which real world? (2014) (26)
- Qué ha supuesto la Guía Española de la EPOC (GesEPOC) y cómo puede mejorar (2016) (26)
- Altitude and COPD prevalence: analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study (2017) (26)
- Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. (2010) (26)
- Asthma-COPD overlap is not a homogeneous disorder: further supporting data (2017) (26)
- Detection of polymorphisms at exons 3 (Tyr113-->His) and 4 (His139-->Arg) of the microsomal epoxide hydrolase gene using fluorescence PCR method combined with melting curves analysis. (2002) (26)
- Face masks, respiratory patients and COVID-19 (2020) (25)
- A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future (2020) (25)
- Nutritional Status of Patients with Chronic Obstructive Pulmonary Disease in Relation to their Physical Performance (2017) (25)
- Documento de consenso «Uso adecuado de los corticoides inhalados en la enfermedad pulmonar obstructiva crónica» (2015) (25)
- Diagnosis of alpha-1 antitrypsin deficiency: a population-based study (2016) (25)
- The variability of respiratory symptoms and associated factors in COPD. (2017) (25)
- Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms (2019) (25)
- Validating the Concept of COPD Control: A Real-world Cohort Study from the United Kingdom (2017) (25)
- The IDDEA project: a strategy for the detection of alpha-1 antitrypsin deficiency in COPD patients in the primary care setting (2011) (25)
- Evaluación del tratamiento sustitutivo del enfisema por déficit de alfa-1-antitripsina (1994) (24)
- Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients (2016) (24)
- Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population. (2020) (24)
- The overlap syndrome between asthma and COPD: implications for management (2011) (24)
- Prevalence and Characteristics of Asthma-COPD Overlap in Routine Primary Care Practices. (2019) (24)
- [Alpha1-antitrypsin deficiency: situation in Spain and development of a screening program]. (2006) (24)
- Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. (2012) (24)
- Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (Gesepoc): The Epoconsul Study. (2018) (24)
- Utility of the antibody response to a conjugated Haemophilus influenzae type B vaccine for diagnosis of primary humoral immunodeficiency. (2000) (23)
- Requisitos para la acreditación de unidades docentes en la especialidad de neumología (2003) (23)
- Update on Asthma–COPD Overlap (ACO): A Narrative Review (2021) (23)
- Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study. (2020) (23)
- [New treatments for chronic obstructive pulmonary disease]. (2005) (23)
- Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management (2016) (23)
- Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids? (2017) (23)
- The Relationship Between 24-Hour Symptoms and COPD Exacerbations and Healthcare Resource Use: Results from an Observational Study (ASSESS) (2016) (23)
- Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus. (2018) (23)
- Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency (2017) (23)
- Déficit de alfa-1-antitripsina. Situación en España y desarrollo de un programa de detección de casos (2006) (23)
- The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis (2016) (22)
- Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease (2018) (22)
- Review: Do we need new antibiotics for treating exacerbations of COPD? (2007) (22)
- Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease (2015) (22)
- Prevalencia y actitudes sobre tabaquismo en población mayor de 40 años (2000) (22)
- Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype (2020) (22)
- The overlap phenotype: the (missing) link between asthma and COPD (2012) (22)
- Quality and strength: the GRADE system for formulating recommendations in clinical practice guidelines. (2013) (22)
- Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease (2020) (22)
- Clinical Characteristics and Risk of Exacerbations Associated With Different Diagnostic Criteria of Asthma-COPD Overlap. (2019) (22)
- Prevalence and Perception of 24-Hour Symptom Patterns in Patients With Stable Chronic Obstructive Pulmonary Disease in Spain. (2016) (22)
- Variabilidad de los síntomas respiratorios en la EPOC grave (2012) (21)
- Estado actual del tratamiento sustitutivo en el enfisema congénito por déficit de alfa-1-antitripsina. Informe del Registro Nacional (1999) (21)
- Prevalence and Perception of 24-h Symptom Patterns in Patients With Stable Chronic Obstructive Pulmonary Disease in Spain (2016) (21)
- [Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. (2022) (21)
- New era for European Respiratory Society clinical practice guidelines: joining efficiency and high methodological standards (2018) (21)
- Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials (2020) (21)
- POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe (2016) (21)
- Validación de la versión traducida del Chronic Obstructive Pulmonary Disease-Population Screener (COPD-PS). Su utilidad y la del FEV1/FEV6 para el diagnóstico de enfermedad pulmonar obstructiva crónica (2012) (21)
- Moxifloxacino frente a amoxicilina en el tratamiento de la neumonía adquirida en la comunidad en América Latina. Resultados de un ensayo clínico multicéntrico (2003) (21)
- Registros de enfermedades respiratorias en España: fundamentos y organización (2011) (20)
- Optimizing bronchodilation in the prevention of COPD exacerbations (2017) (20)
- Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy (2012) (20)
- [Respiratory disease registries in Spain: fundamentals and organization]. (2011) (20)
- Registro español de pacientes con déficit de alfa-1 antitripsina: evaluación de la base de datos y análisis de la población incluida (2017) (20)
- Prevention of exacerbations of COPD with pharmacotherapy (2010) (20)
- First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis (2016) (20)
- Nuevo estudio sobre la prevalencia de la EPOC en España: resumen del protocolo EPISCAN II, 10 años después de EPISCAN (2019) (20)
- Requirements, Strengths and Weaknesses of Inhaler Devices for COPD Patients from the Expert Prescribers' Point of View: Results of the EPOCA Delphi Consensus (2017) (20)
- Variabilidad de la prescripción antibiótica en las infecciones respiratorias en dos países de Europa (2005) (20)
- Prevalence and management of COPD and heart failure comorbidity in the general practitioner setting. (2017) (20)
- Usefulness of the LCOPD, CAFS and CASIS Scales in Understanding the Impact of COPD on Patients (2012) (20)
- Which is the Best Screening Strategy for COPD among Smokers in Primary Care? (2017) (20)
- Recomendaciones ALAT sobre la neumonía adquirida en la comunidad (2001) (20)
- Viral, bacterial or both? Regardless, we need to treat infection in COPD (2014) (19)
- Fracaso en el tratamiento de las agudizaciones de la enfermedad pulmonar obstructiva crónica. Factores de riesgo e importancia clínica (2002) (19)
- Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency (2021) (19)
- The asthma-COPD overlap syndrome: a new entity? (2015) (19)
- Recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC (2001) (19)
- Prevalence of α1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review (2020) (19)
- When is dual bronchodilation indicated in COPD? (2017) (19)
- Antibiotics in exacerbations of COPD: lessons from the past (2004) (19)
- Chronic obstructive pulmonary disease guidelines in Europe: a look into the future (2018) (19)
- Estudio farmacoeconómico del tratamiento antibiótico de las agudizaciones de la bronquitis crónica y la EPOC en Latinoamérica (2003) (19)
- Alpha1-antitrypsin deficiency: epidemiology and prevalence. (2000) (18)
- Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes. (2018) (18)
- Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK: more testing is needed (2018) (18)
- Depressive status explains a significant amount of the variance in COPD assessment test (CAT) scores (2018) (18)
- Emphysema due to α-Antitrypsin Deficiency: Familial Study of the Ybarcelona Variant (2003) (18)
- The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD. (2018) (18)
- Changes in management of chronic obstructive pulmonary disease (COPD) in primary care: EMMEPOC study. (2010) (18)
- Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East–North Africa region, 2017 (2017) (17)
- Factores asociados a la hospitalización por exacerbación de la enfermedad pulmonar obstructiva crónica (2012) (17)
- [COPD and perception of the new GOLD document in Europe. Workshop from the Société de pneumologie de langue française (SPLF)]. (2014) (17)
- Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease (2020) (17)
- [Impact of chronic obstructive pulmonary disease on activities of daily living: results of the EIME multicenter study]. (2007) (17)
- Risk Factors of Poor Outcomes after Admission for a COPD Exacerbation: Multivariate Logistic Predictive Models (2017) (17)
- Identifying possible asthma–COPD overlap syndrome in patients with a new diagnosis of COPD in primary care (2017) (17)
- Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT) (2018) (17)
- It’s time for an aetiology‐based definition of chronic obstructive pulmonary disease (2007) (17)
- Problemas con el diagnóstico de la EPOC en atención primaria (2006) (17)
- Moxifloxacin: a respiratory fluoroquinolone. (2008) (17)
- Neumólogos: ¿adónde vamos, de dónde venimos? (2002) (17)
- Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC). Diagnóstico y tratamiento hospitalario de la agudización (2013) (16)
- Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency (2008) (16)
- Association Between Routine Blood Biomarkers and Clinical Phenotypes and Exacerbations in Chronic Obstructive Pulmonary Disease (2020) (16)
- Economic valuation and determinants of informal care to disabled people with Chronic Obstructive Pulmonary Disease (COPD) (2015) (16)
- Airflow reversibility and long-term outcomes in patients with COPD without comorbidities. (2014) (16)
- Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study (2018) (16)
- Actualización de las recomendaciones ALAT sobre la neumonía adquirida en la comunidad (2004) (16)
- Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency (2018) (16)
- Independent effect of prior exacerbation frequency and disease severity on the risk of future exacerbations of COPD: a retrospective cohort study (2016) (16)
- Predictive value of control of COPD for risk of exacerbations: An international, prospective study (2020) (16)
- Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy (2016) (16)
- Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial (2018) (16)
- Programa de cribado para el déficit de α-antitripsina en pacientes con EPOC mediante el uso de gota de sangre en papel secante (2003) (16)
- Fenotipos clínicos de la EPOC.: Identificación, definición e implicaciones para las guías de tratamiento (2012) (16)
- Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency (2020) (16)
- Comparison of adherence between twice‐ and thrice‐daily regimens of oral amoxicillin/clavulanic acid (2012) (16)
- [Study of the frequency of different phenotypes of alpha-1-antitrypsin in a population of Barcelona]. (1996) (15)
- Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement (2021) (15)
- GOLD in 2017: A View From the Spanish COPD Guidelines (GesCOPD). (2017) (15)
- Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care (2008) (15)
- [Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis]. (2007) (15)
- Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators. (2018) (15)
- Recommendations on non-Pharmacological Treatment in Chronic Obstructive Pulmonary Disease From the Spanish COPD Guidelines (GesEPOC 2017). (2018) (15)
- Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency. (2020) (15)
- Rapid detection of Mmalton α1-antitrypsin deficiency allele by real-time PCR and melting curves in whole blood, serum and dried blood spot samples (2016) (15)
- Caring for patients with COPD and COVID-19: a viewpoint to spark discussion (2020) (15)
- Costes directos de la bronquitis crónica en atención primaria. Análisis de un estudio prospectivo (2001) (15)
- EVALUATION OF CHANGES IN CONTROL STATUS IN COPD: AN OPPORTUNITY FOR EARLY INTERVENTION: Control status is useful for clinical assessment. (2019) (15)
- Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain. (2020) (15)
- A Phase 2 Study To Evaluate The Safety, Tolerability And Efficacy Of Levofloxacin Inhalation Solution (MP-376) Administered For 5 Days Every 28 Days To Prevent Acute Exacerbations In High Risk COPD Patients (2012) (15)
- [Pharmacoeconomic study of antibiotic therapy for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Latin America]. (2003) (15)
- Safety of Rehabilitation Program for COPD Patients. (2017) (15)
- Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study (2021) (15)
- Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough (2016) (14)
- Prevalence and impact of respiratory symptoms in a population of patients with COPD in Latin America: The LASSYC observational study. (2018) (14)
- Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action. (2018) (14)
- Prevalence of alpha-1 antitrypsin deficiency and allele frequency in patients with COPD in Brazil (2016) (14)
- Characterization of the New Alpha-1-Antitrypsin-Deficient PI M-Type Allele, PI Mvall d’hebron (Pro369→Ser) (2000) (14)
- The right treatment for the right patient with COPD: lessons from the IMPACT trial (2020) (14)
- Optimal Bronchodilation for COPD Patients: Are All Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonists the Same? (2018) (14)
- miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease. (2020) (14)
- Identifying patients at risk of late recovery (≥ 8 days) from acute exacerbation of chronic bronchitis and COPD. (2012) (14)
- Multidrug-resistant tuberculosis caused by 'W'-related strains in three immunocompetent foreign-born patients. (1999) (14)
- Clinical Control in COPD: A New Therapeutic Objective? (2020) (14)
- Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease (2002) (14)
- Características de los pacientes con EPOC tratados en neumología en España según grupos GOLD y fenotipos clínicos GesEPOC (2018) (14)
- Características clínicas y riesgo de agudizaciones asociados con diferentes criterios diagnósticos del solapamiento asma-EPOC (2020) (14)
- Prevalencia y percepción de la variabilidad diaria de los síntomas en pacientes con enfermedad pulmonar obstructiva crónica estable en España (2016) (14)
- Recomendaciones sobre tratamiento no farmacológico en la enfermedad pulmonar obstructiva crónica de la Guía española de la EPOC (GesEPOC 2017) (2018) (14)
- Análisis del tabaquismo en España a la luz de los resultados del Estudio IBERPOC (2000) (13)
- Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD (2020) (13)
- Interactive Monitoring Service and COPD: Is it Possible to Reduce Nonadherence? (2015) (13)
- 10 Years After EPISCAN: A New Study on the Prevalence of COPD in Spain -A Summary of the EPISCAN II Protocol. (2019) (13)
- Factors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish registry. (2011) (13)
- What have we learned from observational studies and clinical trials of mild to moderate COPD? (2018) (13)
- Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade (2021) (13)
- Effect of health professional education on outcomes of chronic obstructive pulmonary disease in primary care: A non randomized clinical trial (2013) (13)
- Effectiveness of anti-inflammatory treatment versus antibiotic therapy and placebo for patients with non-complicated acute bronchitis with purulent sputum. The BAAP Study protocol (2011) (13)
- Clinical characteristics and risk of exacerbations associated with different diagnostic criteria of asthma-COPD overlap (2020) (13)
- Efficacy of tiotropium in the prevention of exacerbations of COPD (2009) (13)
- Paciente exacerbador con enfermedad pulmonar obstructiva crónica: recomendaciones en procesos diagnósticos, terapéuticos y asistenciales (2019) (13)
- [Variability of antibiotic prescribing for respiratory tract infections in two European countries]. (2005) (13)
- Utilización de Internet en un estudio multicéntrico sobre EPOC en atención primaria. Fase piloto del estudio EFEMAP (2002) (13)
- Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study. (2019) (13)
- [Development and results of a screening program for COPD in primary care. The PADOC Project(Program for the Increase in the Diagnosis of COPD in Primary Care]. (2000) (12)
- Enfisema pulmonar por déficit de alfa-1-antitripsina. Situación actual y nuevas perspectivas para el tratamiento (1992) (12)
- Informe del Registro Español de Pacientes con Déficit de Alfa-1-Antitripsina (1995) (12)
- Manejo de la enfermedad pulmonar obstructiva crónica en la medicina primaria (1995) (12)
- Asthma-COPD Overlap (ACO) PRO-CON Debate. ACO: Call Me by My Name (2020) (12)
- [A contagiousness study in 3071 familial contacts of tuberculosis patients]. (1997) (12)
- A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology (2011) (12)
- Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment af COPD Exacerbation Syndrome. (2021) (12)
- Tratamiento antimicrobiano de la agudización de la EPOC:: Documento de Consenso 2007* (2008) (12)
- Emphysema due to alpha-antitrypsin deficiency: familial study of the YBARCELONA variant. (2003) (12)
- Usefulness of a patient symptom diary card in the monitoring of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (2012) (12)
- Clinical and inflammatory characteristics of Asthma-COPD overlap in workers with occupational asthma (2018) (12)
- Frequency of Multi-dimensional COPD Indices and Relation with Disease Activity Markers (2013) (12)
- COPD heterogeneity: implications for management (2016) (12)
- An Of fi cial American Thoracic Society / European Respiratory Society Statement : Research Questions in Chronic Obstructive Pulmonary Disease (2015) (12)
- Spanish Implementation of the New International Alpha-1 Anitrypsin Deficiency International Registry: The European Alpha-1 Research Collaboration (EARCO). (2020) (12)
- Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study (2017) (12)
- "Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease": a consensus document. (2015) (12)
- [Pneumology residents trained in Catalonia (1989-1993)]. (1996) (12)
- What was the impact of the Spanish COPD guidelines (GesEPOC) and how can they be improved? (2016) (12)
- Usefulness of the CAT, LCOPD, EQ-5D and COPDSS Scales in Understanding the Impact of Lung Disease in Patients with Alpha-1 Antitrypsin Deficiency (2014) (11)
- Alpha-1-antitrypsin deficiency associated with the Mattawa variant. (2013) (11)
- GesEPOC 2021: One More Step Towards Personalized Treatment of COPD. (2020) (11)
- COPD: JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2004) (11)
- Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease (2015) (11)
- Eficacia clínica del moxifloxacino en el tratamiento de las agudizaciones de la bronquitis crónica. Revisión sistemática y metaanálisis (2007) (11)
- 10 Years After EPISCAN: A New Study on the Prevalence of COPD in Spain—A Summary of the EPISCAN II Protocol (2019) (11)
- Effectiveness and Safety of Inhaled Antibiotics in Patients With Chronic Obstructive Pulmonary Disease. A Multicentre Observational Study. (2021) (11)
- Prevalence and Determinants of COPD in Spain: EPISCAN II (2021) (11)
- Designing Future Clinical Trials for Acute Exacerbations of Chronic Bronchitis (2000) (11)
- Estimación de la variabilidad inicial interobservador de la espirometría forzada en el estudio epidemiológico multicéntrico IBERPOC (1997) (10)
- Antibody deficiency in bronchiectasis (2005) (10)
- Moxifloxacin: a respiratory fluoroquinolone (2008) (10)
- Budesonide/Formoterol Added to Tiotropium Improves the Management of COPD Patients. (2009) (10)
- The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency (2020) (10)
- Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study (2019) (10)
- Tiotropium in chronic obstructive pulmonary disease – a review of clinical development (2020) (10)
- La formación especializada en neumología en Europa. El proyecto HERMES (2009) (10)
- Scintigraphy, angiography and computed tomography in unilateral hyperlucent lung due to obliterative bronchiolitis. (1994) (10)
- Factores de riesgo de elevado coste de las agudizaciones de la bronquitis crónica y la EPOC (2006) (10)
- Utilidad de la cuantífícación de la banda alfa-1 del proteinograma sérico en el cribado del déficit de alfa-1-antitripsina (1998) (10)
- Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD (2015) (10)
- Validation and development of an immunonephelometric assay for the determination of alpha-1 antitrypsin levels in dried blood spots from patients with COPD* (2013) (10)
- Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study (2018) (10)
- Chronic obstructive pulmonary disease (COPD) in Spain and the different aspects of its social impact: a multidisciplinary opinion document (2020) (10)
- [Pulmonary and laryngeal tuberculosis. Study of 26 patients]. (1996) (9)
- Correction: Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial (2010) (9)
- Síntomas respiratorios y diagnóstico de EPOC en fumadores de distintas labores de tabaco. Resultados del estudio IBERPOC (2002) (9)
- Analysis of Blood Biomarkers in Patients with Chronic Obstructive Pulmonary Disease (COPD) and with Asthma-COPD Overlap (ACO) (2020) (9)
- Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD (2021) (9)
- What was the Impact of the Spanish COPD Guidelines (GesEPOC) and how can They be Improved (2016) (9)
- External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study (2019) (9)
- [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial]. (2003) (9)
- Control clínico en la EPOC: ¿un nuevo objetivo terapéutico? (2020) (9)
- Infección tuberculosa en estudiantes de enfermería. Prevalencia y virajes durante 3 años de seguimiento (1999) (9)
- Time To Revise COPD Treatment Algorithm (2019) (9)
- Compliance with guidelines in the treatment of asthma exacerbations in primary care (2011) (9)
- Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials (2020) (9)
- Application of a diagnostic algorithm for the rare deficient variant Mmalton of alpha-1-antitrypsin deficiency: a new approach (2016) (9)
- Patients with Chronic Obstructive Pulmonary Disease Exacerbations: Recommendations for Diagnosis, Treatment and Care. (2019) (9)
- Multiple Score Comparison: a network meta-analysis approach to comparison and external validation of prognostic scores (2017) (9)
- La formación especializada en neumología en Europa. El proyecto HERMES (2009) (9)
- ROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group (2021) (8)
- Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective (2018) (8)
- Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care (2018) (8)
- Actualización 2021 de la guía española de la EPOC (GesEPOC). Diagnóstico y tratamiento del síndrome de agudización de la EPOC (2022) (8)
- COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population (2020) (8)
- Combining case-finding methods for COPD in primary care: a large, two-stage design study. (2018) (8)
- [Recommendations for the care of the patient with chronic obstructive pulmonary disease]. (2001) (8)
- Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (GesEPOC): The Epoconsul Study (2018) (8)
- Impact of C-reactive protein testing on adherence to thrice-daily antibiotic regimens in patients with lower respiratory tract infection. (2010) (8)
- Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial (2020) (8)
- [Molecular characterization of two variants of alpha-1-antitrypsin deficiency: PI Mpalermo and PI Plovel]. (1997) (8)
- Déficit de alfa-1-antitripsina asociado a la variante Matawa (2013) (8)
- Factors Associated With the Evolution of Lung Function in Patients With Alpha-1 Antitrypsin Deficiency in the Spanish Registry (2011) (8)
- Viajar con oxígeno. Reflexiones a propósito de la primera reunión internacional de pacientes con déficit de alfa-1-antitripsina (2004) (8)
- GesEPOC 2021: un paso más en la personalización del tratamiento de la EPOC (2020) (8)
- A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid (2022) (8)
- Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial (2017) (8)
- Update to the Latin American Thoracic Association (ALAT) Recommendations on Infectious Exacerbation of Chronic Obstructive Pulmonary Disease. (2004) (7)
- Association between circulating alpha-1 antitrypsin polymers and lung and liver disease (2021) (7)
- Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis (2021) (7)
- Tratamiento aumentativo para el enfisema por déficit de alfa-1 antitripsina: Pro (2018) (7)
- Alpha1-antitrypsin deficiency: the contribution of national registries to the understanding of the disorder. A journal Supplement in memory of Professor Maurizio Luisetti (2015) (7)
- Documento de consenso «Uso adecuado de los corticoides inhalados en la enfermedad pulmonar obstructiva crónica» (2015) (7)
- Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Recommendations for Diagnosis, Treatment and Care (2019) (7)
- Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease (2015) (7)
- Prevalence of smoking in a psychiatric hospital and its relationship with respiratory symptoms and the prevalence of COPD (2018) (7)
- Normativas de diagnóstico y tratamiento del déficit de alfa-1 antitripsina Asociación Argentina de Medicina Respiratoria (2014) (7)
- The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS (2014) (7)
- Erratum to: Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management (2017) (7)
- Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data (2020) (7)
- [Treatment of chronic bronchitis and chronic pulmonary obstructive disease in primary care]. (1999) (7)
- Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration (2020) (7)
- Erratum: Respiratory guidelines - Which real world? (Annals of the American Thoracic Society (2014) 11, (S85-S91)) (2014) (7)
- CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care (2021) (7)
- Tratamiento antimicrobiano de la agudización de la EPOC: Documento de Consenso 2007* (2008) (7)
- Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency (2021) (7)
- TB or not TB: update from the ERS Respiratory Infection Assembly 10 (2010) (7)
- Development of a simple binary response questionnaire to identify airflow obstruction in a smoking population in Argentina (2015) (6)
- Towards a patient-oriented treatment of COPD. (2016) (6)
- Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD: Chest 2005;127(4):1212–8. (2005) (6)
- Genetic diagnosis of α1-antitrypsin deficiency using DNA from buccal swab and serum samples (2017) (6)
- Multidisciplinary Perspectives on the Importance of Physical Activity in COPD. (2019) (6)
- [Tuberculous infection in nursing students: prevalence and conversion during a 3-year follow-up]. (1999) (6)
- [Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease]. (2006) (6)
- Health status and costs of exacerbations of chronic bronchitis and COPD: how to improve antibiotic treatment (2005) (6)
- COUNTERPOINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? No. (2018) (6)
- Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients? (2017) (6)
- Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life (2010) (6)
- Efficacy of high doses of oral penicillin versus amoxicillin in the treatment of adults with non-severe pneumonia attended in the community: study protocol for a randomised controlled trial (2013) (6)
- Easy to Perform Physical Performance Tests to Identify COPD Patients with Low Physical Activity in Clinical Practice (2020) (6)
- Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review (2022) (6)
- Knowledge of Chronic Obstructive Pulmonary Disease, Presence of Chronic Respiratory Symptoms and Use of Spirometry Among the Spanish Population: CONOCEPOC 2019 study. (2020) (6)
- Reduction in COPD exacerbations during COVID-19: a systematic review and meta-analysis (2021) (6)
- GesEPOC 2021: One More Step Towards Personalized Treatment of COPD (2021) (6)
- Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK (2018) (6)
- Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews (2022) (6)
- Enfisema por déficit de alfa-1-antitripsina: ¿es realmente una enfermedad infrecuente? (2004) (6)
- Implementation of European Alpha-1 Research Collaboration (EARCO) in Portugal: the future starts now. (2020) (6)
- PRDM15 Is Associated with Risk of Chronic Obstructive Pulmonary Disease in a Rural Population in Chile (2020) (6)
- ¿Cómo podemos identificar a los pacientes con fenotipo mixto asma-EPOC (ACOS) en la práctica clínica? (2016) (6)
- La calidad de vida en los pacientes con enfermedad pulmonar obstructiva crónica: criterios de cuantificación y repercusiones terapéuticas (2005) (6)
- Tratamiento farmacológico de las agudizaciones infecciosas de la EPOC (2007) (6)
- ADDITION OF BUDESONIDE/FORMOTEROL TO TIOTROPIUM REDUCES THE NUMBER OF EXACERBATION DAYS COMPARED WITH TIOTROPIUM ALONE (2009) (5)
- Previous outpatient antibiotic use in patients admitted to hospital for COPD exacerbations: room for improvement (2013) (5)
- BUDESONIDE/FORMOTEROL ADDED TO TIOTROPIUM PROVIDES RAPID IMPROVEMENTS IN LUNG FUNCTION AND ABILITY TO UNDERTAKE MORNING ACTIVITIES (2009) (5)
- Screening for polymorphisms in exon 5 of the glutathione S-transferase Pl gene (2000) (5)
- Definition and aetiology of non-CF bronchiectasis. (2013) (5)
- [The cost of chronic obstructive pulmonary disease in Spain: options for optimizing resources]. (2001) (5)
- Traveling With Oxygen: Thoughts on the First International Meeting of Patients With Alpha 1-Antitrypsin Deficiency (2004) (5)
- Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes (2018) (5)
- [Evaluation of replacement therapy in emphysema caused by alpha 1-antitrypsin deficiency]. (1994) (5)
- [ALAT (Latin American Thoracic Association) recommendations on community-acquired pneumonia]. (2001) (5)
- Impact of chronic bronchial infection on the lungs and beyond. (2013) (5)
- Estimated Prevalence and Number of PiMZ Genotypes of Alpha-1 Antitrypsin in Seventy-Four Countries Worldwide (2021) (5)
- Amerindian Ancestry Influences Genetic Susceptibility to Chronic Obstructive Pulmonary Disease (2020) (5)
- Exacerbations of chronic obstructive pulmonary disease (2006) (5)
- Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population (2020) (5)
- Reliability of a self-administered diary of symptoms for assessing the evolution of acute bronchitis. (2012) (5)
- Characteristics of candidates for lung transplantation due to chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency emphysema. (2015) (5)
- How whole-body vibration can help our COPD patients. Physiological changes at different vibration frequencies (2018) (5)
- How can we identify patients with asthma-COPD overlap syndrome in clinical practice? (2016) (5)
- Determinants of blood eosinophil levels in the general population and patients with COPD: a population-based, epidemiological study (2022) (5)
- ALAT recommendations on infectious exacerbation of COPD (2001) (5)
- Actualización de la Guía Española de la EPOC (GesEPOC): comorbilidades, automanejo y cuidados paliativos (2021) (4)
- Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study (2021) (4)
- Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency (2021) (4)
- Enfisema por déficit de alfa-1-antitripsina: ¿es realmente una enfermedad infrecuente? (2004) (4)
- Modifying the clinical course of COPD (2006) (4)
- Determining Factors in the Prescription of Moxifloxacin in Exacerbations of Chronic Bronchitis in the Primary-Care Setting (2007) (4)
- ¿Debemos administrar tratamiento sustitutivo a los pacientes con déficit de alfa-1-antitripsina? (1998) (4)
- Preventing readmissions of COPD patients: more prospective studies are needed (2020) (4)
- Fiabilidad del registro del diagnóstico de la enfermedad pulmonar obstructiva crónica en Atención Primaria (2017) (4)
- Inappropriate prescriptions following initial COPD diagnosis (2013) (4)
- Blood eosinophil count predicts treatment failure and hospital readmission for COPD (2020) (4)
- Geographical Distribution of COPD Prevalence in the Americas (2018) (4)
- Spanish COPD Guidelines (GesEPOC 2021): Non-pharmacological Treatment Update. (2021) (4)
- [Screening program for alpha-1 antitrypsin deficiency in patients with chronic obstructive pulmonary disease, using dried blood spots on filter paper]. (2003) (4)
- Caminar al menos 30 minutos al día 5 días por semana. ¿Por qué y cómo prescribir ejercicio físico en la enfermedad pulmonar obstructiva crónica? (2015) (4)
- Long-term antibiotics in COPD: more benefit than harm? (2013) (4)
- Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset (2014) (4)
- PRS39 VALIDATION OF THE SPANISH VERSION OF THE “COPD AND ASTHMA SLEEP IMPACT SCALE (CASIS)” QUESTIONNAIRE (2009) (4)
- [Treatment failure of acute exacerbations of chronic obstructive airways disease risk factors and clinical relevance]. (2002) (4)
- Physical Activity Levels and Associated Factors in a Latin American COPD Population of Patients. The LASSYC Study (2021) (4)
- [Use of the Internet in a multicenter study of chronic obstructive pulmonary disease in primary care. Pilot phase of the EFEMAP study]. (2002) (4)
- Long-term effect of α1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database (2021) (4)
- Erratum: Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study (2017) (4)
- Are short courses of antibiotic therapy as effective as standard courses for COPD exacerbations? A systematic review and meta-analysis. (2022) (4)
- [Validation of the Spanish version of the Chronic Obstructive Pulmonary Disease-Population Screener (COPD-PS). Its usefulness and that of FEV₁/FEV₆ for the diagnosis of COPD]. (2012) (4)
- Prevention and treatment of exacerbations of non-CF bronchiectasis. (2013) (4)
- Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future? (2018) (4)
- Efficacy and safety of discontinuing antibiotic treatment for uncomplicated respiratory tract infections when deemed unnecessary. A multicentre, randomised clinical trial in primary care. (2021) (4)
- Your racing horses will help you to quit: a lesson for COPD and α1-antitrypsin deficiency research (2009) (4)
- [Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): recruitment and field work]. (1999) (4)
- Acute bronchitis: aetiology and treatment. (2013) (4)
- Analyzing the pathway to triple therapy in COPD patients: A retrospective database analysis (2014) (4)
- Geographic distribution of chronic obstructive pulmonary disease prevalence in Africa, Asia and Australasia. (2019) (4)
- Vacuna antineumocócica. Antiguas controversias y nuevas indicaciones (I) (1998) (4)
- Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database (2021) (4)
- [Respiratory symptoms and diagnosis of COPD in smokers of various types to tobacco. Results from the IBERPOC study]. (2002) (4)
- [Translated article] Spanish COPD Guidelines (GesEPOC 2021): Non-pharmacological Treatment Update. (2022) (4)
- Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care. (2021) (3)
- Qué ha supuesto la Guía Española de la EPOC (GesEPOC) y cómo puede mejorar (2016) (3)
- Degree of knowledge among physicians about the diagnosis and treatment of alpha-1 antitrypsin deficiency (2015) (3)
- Electrophoretic α1-globulin for screening of α1-antitrypsin deficient variants (2020) (3)
- Is C-reactive protein testing useful to predict outcome in patients with acute bronchitis? (2014) (3)
- Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento no farmacológico (2021) (3)
- [Reliability of a chronic obstructive pulmonary disease diagnosis register in Primary Care]. (2017) (3)
- Connected real-life research, a pillar of P4 medicine (2020) (3)
- Diaphragmatic Movement at Rest and After Exertion: A Non-Invasive and Easy to Obtain Prognostic Marker in COPD (2022) (3)
- Withdrawal of inhaled corticosteroids in COPD (2020) (3)
- Rate of Comorbidities During the 4-Year UPLIFT Trial in COPD: A Post Hoc Analysis (2014) (3)
- Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire (2018) (3)
- Importancia de la medición de la interleucina 6 en suero como mediador de inflamación sistémica en pacientes con deficiencia de alfa-1-antitripsina (2002) (3)
- Prescripción de actividad física en la enfermedad pulmonar obstructiva crónica… y más allá (2017) (3)
- Exacerbations in COPD: a personalised approach to care. (2023) (3)
- Chronic obstructive pulmonary disease: the treatment (Part One) (2006) (3)
- Efecto de AM3 en la calidad de vida de pacientes con enfermedad pulmonar obstructiva crónica en subgrupos de riesgo (2008) (3)
- Diagnosis of asthma-COPD overlap: Is it possible a global definition? (2018) (3)
- PRS22 COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN SPAIN. (2009) (3)
- Perception Of Symptom Variability In Patients With Severe COPD: Impact On Morning Activities And Therapeutic Behaviour (2010) (3)
- Ischiocrural Strength May Be a Better Prognostic Marker Than Quadriceps Strength in COPD (2018) (3)
- Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study (2017) (3)
- The living with chronic obstructive pulmonary disease scale was successfully adapted for use in Southern European (Italian and Spanish) and Eastern European (Russian) cultures. (2012) (3)
- Knowledge of chronic obstructive pulmonary disease, presence of chronic respiratory symptoms and use of spirometry among the Spanish population: CONOCEPOC 2019 study. (2021) (3)
- Corticoides inhalados en la EPOC por fenotipo en lugar de por gravedad.: Argumentos a favor (2011) (3)
- The challenge of diagnosing a mixed asthma–COPD phenotype (ACOS) in clinical practice (2016) (3)
- Demographic and clinical characteristics of patients with α1-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO (2022) (3)
- A PI*MS is not always a PI*MS. An example of when genotyping for alpha-1 antitrypsin deficiency is necessary. (2020) (3)
- [The use of human gamma globulin in the treatment of common variable immunodeficiency]. (1995) (3)
- Treatment with inhaled α1-antitrypsin: a square peg in a round hole? (2019) (3)
- Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain (2022) (3)
- Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory (2020) (3)
- Expanding the spectrum of European Respiratory Society official scientific documents: short documents complement clinical practice guidelines, statements and technical standards (2020) (3)
- [Prevalence of and attitudes towards smoking in a population over 40 years of age]. (2000) (3)
- Late Breaking Abstract - A New study of the Prevalence of COPD in Spain: EPISCAN II (2019) (3)
- Pulmonary Rehabilitation… Yes But No. (2019) (2)
- Improving physical activity in patients with severe COPD with urban walking circuits. A randomised trial (2013) (2)
- COPD exacerbations in old age: how to prevent, detect and treat (2009) (2)
- The concept of control in chronic obstructive pulmonary disease: Development of the criteria and validation for use in clinical practice (2020) (2)
- Meeting abstracts from the Respiratory Effectiveness Group 2015 Winter Summit – databases and registries around the world: maximizing the yield (2015) (2)
- [IgG subclasses in patients with symptomatic IgA deficiency]. (1995) (2)
- The Impact of Chronic Bronchial Infection in COPD: A Proposal for Management (2022) (2)
- Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials (2014) (2)
- Real-life asthma impairment: SABA use depends on smoking phenotype (2013) (2)
- Heterogeneity in prevalence and underdiagnosis of COPD: Results from BOLD, EPI-SCAN, PLATINO, and PREPOCOL (2013) (2)
- Five questions in chronic obstructive pulmonary disease (2013) (2)
- Alpha1-anti-trypsin deficiency: epidemiology and incidence. (2002) (2)
- A Pooled Analysis of Mortality in Patients with COPD Receiving Triple Therapy versus Dual Bronchodilation (2021) (2)
- ALAT recommendations on community-acquired pneumonia (2001) (2)
- Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group (2022) (2)
- Nuevo documento europeo sobre el déficit de alfa-1 antitripsina: de la teoría a la práctica diaria (2018) (2)
- Características de la población candidata a trasplante pulmonar por enfermedad pulmonar obstructiva crónica y por enfisema secundario a déficit de alfa 1 antitripsina (2015) (2)
- Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients (2015) (2)
- COPD Maintenance Therapy with Tiotropium/Olodaterol Versus LABA/ICS: An Assessment of the Risk of Treatment Escalation and Adverse Outcomes in Over 40,000 Patients (2020) (2)
- The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(Mattawa)/Q0(ourém). (2020) (2)
- [Antipneumococcal vaccines. Old controversies and new indications (II)]. (1998) (2)
- LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations (2022) (2)
- Spanish implementation of the new international alpha-1 anitrypsin deficiency international registry: The European Alpha-1 Research Collaboration (EARCO) (2021) (2)
- Medicina basada en la no-evidencia: el ejemplo del uso de los corticosteroides sistémicos en la agudización de la EPOC (2017) (2)
- [A report on the Spanish Registry of Patients with Alpha 1-Antitrypsin Deficiency. The Alpha 1-Antitrypsin Deficiency Study Group]. (1995) (2)
- The ever-expanding ERS fellowship programmes: achievements over the past 3 years (2016) (2)
- Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment af COPD Exacerbation Syndrome (2021) (2)
- PRS42 VALIDATION OF THE SPANISH VERSION OF THE “COPD AND ASTHMA FATIGUE SCALE (CAFS)” QUESTIONNAIRE (2009) (2)
- [Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups]. (2008) (2)
- Fiabilidad de un diario de síntomas autoadministrado para evaluar la evolución de la bronquitis aguda (2012) (2)
- CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients (2022) (2)
- [Individually-tailored treatment of chronic obstructive pulmonary disease: a proposed change]. (2009) (2)
- Conocimiento de la enfermedad pulmonar obstructiva crónica, presencia de síntomas respiratorios crónicos y uso de la espirometría en la población española: estudio CONOCEPOC 2019 (2020) (2)
- Enfermedad pulmonar obstructiva crónica: ¿enfermedad o síndrome de zugzwang? (2008) (2)
- [Residency training of European respiratory medicine specialists: The HERMES project]. (2009) (2)
- Diagnostic Criteria for the Asthma-COPD Overlap (ACO) Still Room for Improvement (2017) (2)
- Virus-bacteria interactions in COPD exacerbations. (2013) (2)
- Excess inhaled corticosteroid adherence may be a marker of uncontrolled asthma (2013) (2)
- HLA-DRB1 Alleles are Associated With COPD in a Latin American Admixed Population. (2020) (2)
- Antibiotics for chronic bronchitis: a meta-analysis that speaks only four languages (2007) (2)
- Is It Possible to Reduce the Use of Antibiotics in Severe Exacerbations of Chronic Obstructive Pulmonary Disease? (2008) (2)
- Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry (2022) (2)
- Augmentation Therapy for Emphysema due to Alpha-1 Antitrypsin Deficiency: Pro (2018) (2)
- Long-Term Risk of Mortality Associated with Isolation of Pseudomonas aeruginosa in COPD: A Systematic Review and Meta-Analysis (2022) (2)
- Chronic bronchial infection/colonisation: aetiology and mechanisms. (2013) (2)
- Spirometric screening and survey of knowledge on COPD and smoking in Spanish political representatives: The ConSePOC study (2011) (2)
- Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain (2021) (2)
- Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis (2022) (2)
- GesEPOC 2021 and GOLD 2021. Closer Together or Further Apart? (2021) (2)
- Predictors of poor outcome in severe hospitalised COPD exacerbations (2011) (2)
- Current thinking and new paradigm for COPD. (2016) (1)
- Definition and aetiology of infective exacerbations of COPD. (2013) (1)
- GesEPOC 2021 y GOLD 2021. ¿Más cerca o más lejos? (1)
- CHRONIC OBSTRUCTIVE PULMONARY DISEASE Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study (2012) (1)
- [Usefulness of the quantification of the alpha-1 serous protein band in the screening of alpha-1-antitrypsin deficiency]. (1998) (1)
- Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil (2021) (1)
- Análisis de coste-efectividad de tiotropio en el tratamiento de la EPOC en España (2010) (1)
- [Translated article] Spanish COPD Guidelines (GesEPOC) 2021 Update. Diagnosis and Treatment of COPD Exacerbation Syndrome. (2022) (1)
- Diagnosis of alpha1-antitrypsin deficiency not just in severe COPD. (2018) (1)
- Mediators of Inflammation in Pulmonary Diseases (2015) (1)
- PRS17 VALIDATION OF THE COPD SEVERITY SCORE FOR USE IN THE SPANISH PRIMARY HEALTH CARE SYSTEM, THE NEREA STUDY: PRELIMINARY RESULTS (2006) (1)
- Diagnóstico, estratificación, tratamiento y seguimiento de los pacientes con EPOC en función de su complejidad: Proyecto Expert Meeting (2018) (1)
- Association between blood eosinophil count and risk of exacerbations in patients with COPD (2017) (1)
- The asthma–COPD overlap syndrome (2015) (1)
- Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results (European Respiratory Journal (2012) 40, (17-27)) (2012) (1)
- Sputum Purulence Guided Antibiotic Therapy In Patients With Severe Exacerbations Of COPD (2010) (1)
- Pharmacotherapy of COPD in Central and Eastern Europe - The POPE study (2016) (1)
- Cost-Effectiveness Of Umeclidinium/Vilanterol In Symptomatic Copd Spanish Patients. (2015) (1)
- Are There Differences Between the Available Treatments for Emphysema Associated with Alpha-1 Antitrypsin Deficiency? (2018) (1)
- Is it asthma, is it bronchiectasis…or is it an alpha-1-antitrypsin deficiency? (2011) (1)
- Unravelling young COPD and pre-COPD in the general population (2022) (1)
- Identifying cut off scores for the chronic obstructive pulmonary disease assessment test (CAT) to predict exacerbations in COPD (2017) (1)
- Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study. (2022) (1)
- GOLD en 2017:: una visión desde la Guía Española de la EPOC (GesEPOC) (2017) (1)
- SERIES “THE GLOBAL BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” #1: Epidemiology and costs of chronic obstructive pulmonary disease (2006) (1)
- PRS41 VALIDATION OF THE SPANISH VERSION OF THE “LIVING WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (LCOPD)” QUESTIONNAIRE (2009) (1)
- Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration (2022) (1)
- COPD: Journal of Chronic Obstructive Pulmonary Disease. Preface. (2015) (1)
- How can Patients With Asthma-COPD Overlap Syndrome in Clinical Practice be Identified?☆ (2016) (1)
- Chronic obstructive pulmonary disease: definition, epidemiology and diagnostic procedures (2006) (1)
- Long-Term Evolution of Lung Function in Patients with alpha 1-Antitrypsin Deficiency. (2009) (1)
- Exacerbations of COPD (2019) (1)
- Assessing the impact of COPD on sleep quality with the CASIS questionnaire (2019) (1)
- Residency Training of European Respiratory Medicine Specialists: The HERMES Project (2009) (1)
- Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain (1)
- C-reactive protein point of care testing: the answer to antibiotic prescribing in ambulatory patients with exacerbations of chronic obstructive pulmonary disease? (2020) (1)
- Clinical and spirometric variables are better predictors of COPD exacerbations than routine blood biomarkers. (2020) (1)
- Improving morning activities in COPD patients with budesonide/formoterol: Assessment of data from two randomised trials using minimal important differences from a morning activities questionnaire (2010) (1)
- More evidence is required for short-term treatment of exacerbations of chronic obstructive pulmonary disease: 3 days or no antibiotic at all? (2007) (1)
- “Treatment patterns in the newly diagnosed COPD patients in Catalonia between 2007-2012” (2014) (1)
- Frequency and Associated Factors of Suicidal Ideation in Patients with Chronic Obstructive Pulmonary Disease (2022) (1)
- Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain (2022) (1)
- [Don't forget to walk at least 30 minutes per day 5 days a week. Why and how to prescribe physical exercise in chronic obstructive pulmonary disease]. (2015) (1)
- [Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care. (2022) (1)
- [Importance of serum interleukin-6 as a mediator of systemic inflammation in patients with alpha-1 antitrypsin deficiency]. (2002) (1)
- P116 Observational study to characterise 24-hour COPD symptoms: cross-sectional results from the ASSESS study (2013) (1)
- Airflow reversibility on long term outcomes of patients with COPD (2014) (1)
- [Pleural effusion secondary to a malignant thoracic schwannoma]. (1992) (1)
- Taken to task: what is and is not an appropriate response to an ERS guidelines task force? (2017) (1)
- Are C-reactive protein levels associated with bacteria in COPD exacerbations? (2015) (1)
- Late-breaking abstract: Moxifloxacin (MXF) vs amoxicillin/clavulanic acid (AMC) in acute exacerbations of COPD (AECOPD): Results of a large clinical trial with a novel endpoint (2011) (1)
- Determinants in the Underdiagnosis of COPD in Spain—CONOCEPOC Study (2022) (1)
- Prevalence of bronchiectasis in four European countries (2016) (1)
- Is it Asthma, is it Bronchiectasis…or is it an Alpha-1-Antitrypsin Deficiency?☆ (2011) (1)
- Rehabilitación pulmonar… sí pero no (2019) (1)
- [Emphysema caused by alpha 1-antitrypsin deficit. New preventive and therapeutic measures]. (1993) (1)
- Neutrophil elastase gene expression and relation with lung function in Alpha-1 Antitrypsin deficiency patients (2017) (1)
- Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients? (2017) (1)
- The role of inhaled antibiotics in bronchial infection. (2013) (1)
- ¿Existen diferencias entre los tratamientos disponibles para el enfisema pulmonar por déficit de alfa-1 antitripsina? (2018) (1)
- ¿Es asma, son bronquiectasias, o es un déficit de alfa-1-antitripsina? (2011) (1)
- Pharmacologic Management Strategies of Asthma-Chronic Obstructive Pulmonary Disease Overlap. (2022) (1)
- Correction: Clinical and inflammatory characteristics of Asthma-COPD overlap in workers with occupational asthma (2018) (1)
- Respiratory symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scores) and GOLD-ABCD COPD classification: the LASSYC study. (2021) (1)
- Long-term evolution of individuals with alpha1 antitrypsin deficiency from the Spanish registry (2015) (1)
- Non-eosinophilic severe exacerbations of COPD: what about antibiotics? (2019) (1)
- KEY POINTS Chronic bronchial infection is associated with increased pulmonary and systemic inflammation and is a risk factor for accelerated progression of COPD (2015) (0)
- Chronic obstructive pulmonary disease: the exacerbation (2006) (0)
- [The current state of substitution treatment in congenital emphysema due to alpha-1-antitrypsin deficiency. The report of the National Registry]. (1999) (0)
- Faculty Opinions recommendation of Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. (2011) (0)
- Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population (2022) (0)
- Prediction of liver-related endpoints by non-invasive fibrosis tests – longitudinal follow-up in adults with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype) (2023) (0)
- Chronic bronchitis: from an old syndrome to a new phenotype (2012) (0)
- Bone health of patients with COPD in relation to their exercise capacity and gait speed (2019) (0)
- The Best on Infections, update from the 2010 ERS Conference (2011) (0)
- COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy (2020) (0)
- What We Talk about When We Talk about Exacerbations of Chronic Obstructive Pulmonary Disease. (2019) (0)
- Variations in Chronic Obstructive Pulmonary Disease Outpatient Care in Respiratory Clinics: Results From the 2021 EPOCONSUL Audit. (2023) (0)
- Assessment of symptoms in COPD: the importance of morning symptoms (2014) (0)
- Maestral (Moxifloxacin In AECB Superiority Trial) Study Protocol: Use Of A Novel 8-Week Post-Therapy Endpoint (2011) (0)
- Cost-Effectiveness Analysis of Umeclidinium Bromide/Vilanterol 62.5/25 MCG Versus Tiotropium/Olodaterol 5/5 MCG in Symptomatic Patients with Chronic Obstructive Pulmonary Disease in Spain (2018) (0)
- S46 Blood eosinophil counts and risk of short-term hospital readmission for COPD exacerbation (2018) (0)
- Dissociation between physical capacity and daily physical activity in COPD patients. A population-based approach. (2023) (0)
- ResearchSystemic inflammation in chronic obstructive pulmonary disease : a population-based study (2010) (0)
- The European Alpha-1 antitrypsin Deficiency Research Collaboration (EARCO). A new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency (2019) (0)
- Trends of COPD in Spain: Changes Between Cross Sectional Surveys 1997, 2007 and 2017. (2022) (0)
- How to get the most out of the ERS International Congress 2021 and an overview of the Early Career Member session (2021) (0)
- Gene expression network in PiZZ Alpha1 Antitrypsin Deficiency and its relationship with the severity of lung disease (2017) (0)
- Characteristics of individuals with alpha-1 antitrypsin deficiency from Northern and Southern European countries: EARCO international registry (2023) (0)
- Cardiovascular comorbidity in severe COPD patients (2017) (0)
- Systemic Inflammatory Markers in COPD Versus Healthy Subjects from a Population Sample: Findings from the EPI-SCAN Study. (2009) (0)
- Contents, Vol. 61, 1994 (1994) (0)
- Multidisciplinary Perspectives on the Importance of Physical Activity in COPD (2019) (0)
- [Chronic obstructive pulmonary disease: disease or Zugzwang's syndrome?]. (2008) (0)
- [Chronic obstructive pulmonary disease. Impact and exacerbations]. (2004) (0)
- [Antipneumococcal vaccine. Old controversies and new indications]. (1998) (0)
- Clinical approach to the diagnosis and assessment of AATD (2019) (0)
- [The management of chronic obstructive pulmonary disease in primary medicine]. (1995) (0)
- The best on infections: update from the 2010 ERS Congress (2011) (0)
- [Translated article] GesEPOC 2021 and GOLD 2021. Closer together or further apart? (2022) (0)
- Recommendations of SEPAR (2015) (0)
- [Emphysema due to alpha-1-antitrypsin deficiency: is it really an uncommon disease?]. (2004) (0)
- Perception Of Symptom Variability In Patients With Symptomatic COPD (2010) (0)
- [Pneumothorax and pneumomediastinum after bronchoalveolar lavage: can be avoided?]. (1995) (0)
- Distribution and determinants of restrictive functional pattern (2011) (0)
- Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil (2013) (0)
- Pulmonary rehabilitation… yes but no (2019) (0)
- University of Birmingham Diagnosis and management of Alpha 1 Antitrypsin deficiency in Europe (2019) (0)
- Lyme disease in paediatrics (2018) (0)
- COPD_A_268421 2621..2627 (2020) (0)
- Obstructive Airways Disease Epidemiology of Chronic Obstructive Pulmonary Disease Exacerbations (2002) (0)
- Non-evidence based medicine: example of the use of systemic corticosteroids in exacerbation of COPD. (2017) (0)
- Physician perspectives: barriers to diagnosing and treating severe AATD (2017) (0)
- Antibiotic treatment and prevention of exacerbations of COPD. (2013) (0)
- Incidence and burden of major comorbidities among individuals with COPD: a comprehensive analysis using data from primary care (2009) (0)
- Do Patients In Tiotropium Clinical Trials In COPD Reflect Clinicians Reality? An Analysis Of A Pooled Clinical Trial Database (2010) (0)
- Effects of antibiotics on exacerbation-free intervals in patients with chronic bronchitis and chronic obstructive pulmonary disease (2006) (0)
- Nutritional status and physical activity in patients with COPD, and factors associated with malnutrition (2019) (0)
- Validation of the COPD control concept: A UK pilot (2016) (0)
- The role of viruses in chronic bronchitis and exacerbations of COPD. (2013) (0)
- Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study (2023) (0)
- [Accreditation requirements for educational programs in respiratory medicine]. (2003) (0)
- Factors associated with self-reported reduced walking time in patients with COPD (2016) (0)
- Researchinflammation in chronic obstructive pulmonary disease: a population-based study (2010) (0)
- Faculty Opinions recommendation of Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease. (2013) (0)
- Chronic obstructive pulmonary disease: etiology and natural history (2006) (0)
- [Introduction. COPD]. (2009) (0)
- Should Age Be Part of Multidimensional Indices of Risk in Chronic Obstructive Pulmonary Disease (2015) (0)
- Comparison of two models of factors associated to hospital admission for COPD (2011) (0)
- Characterization of patients with severe COPD (2018) (0)
- TIOTROPIUM/OLODATEROL THERAPY IMPROVES LUNG FUNCTION, SYMPTOMS AND IMPACT OF DISEASE VS MONOTHERAPIES IN STEROID-FREE PATIENTS WITH COPD (2019) (0)
- Russian guidelines for the management of COPD: algorithm of pharmacologic treatment [Corrigendum] (2019) (0)
- ' s response to reviews Title : Pseudomonas aeruginosa isolates in severe Chronic Obstructive Pulmonary Disease : characterization and risk factors (2014) (0)
- COPD_A_342220 245..258 (2022) (0)
- LATE-BREAKING ABSTRACT: Phenotypes of COPD in central and Eastern Europe - The POPE study (2015) (0)
- Impact of age-related comorbidities on the risk of COPD exacerbations in subjects with severe airflow limitation: A pan-European study (2013) (0)
- miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease. (2021) (0)
- “Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results”. Robert Wilson, Antonio Anzueto, Marc Miravitlles, Pierre Arvis, Jeff Alder, Daniel Haverstock, Mila Trajanovic and Sanjay Sethi. Eur Respir J 2012; 40: 17–27. (2012) (0)
- AB030. Prevalence and incidence of bronchiectasis in Catalonia in 2012 (2016) (0)
- New advances in smoking cessation (2006) (0)
- Differential diagnosis of obstructive lung diseases: asthma and COPD (2011) (0)
- COPD_A_322793 3131..3143 (2021) (0)
- Sex differences in COPD outcome in 5,355 women with COPD: A new analysis of the 3CIA study (2020) (0)
- University of Southern Denmark Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation Hamesch, (2019) (0)
- Modern epidemiology of alpha1-antitrypsin deficiency (AATD) in the UK (2018) (0)
- Moving forward with Therapeutic Advances in Respiratory Disease (2012) (0)
- Correction to: Association between circulating alpha-1 antitrypsin polymers and lung and liver disease (2021) (0)
- Adherence to inhaled therapies in COPD patients from 7 Latin America countries: the LASSYC study (2017) (0)
- Biomarkers of coagulative properties in patients admitted with AECOPD. (2022) (0)
- Comorbidity Burden in Clinical Trials versus Clinical Practice (2010) (0)
- New variants of alpha-1-antitrypsin: structural simulations and clinical expression (2022) (0)
- Impact of new treatments on chronic obstructive pulmonary disease guidelines (2012) (0)
- Change in the COPD assessment test (CAT) score as predictor of short-term evolution of patients admitted for an exacerbation of COPD (2014) (0)
- Sputum colour: a marker of bacterial infection. (2013) (0)
- P60 COPD-related health care costs for GOLD C/D patients with elevated blood eosinophil counts (2018) (0)
- Physician perspectives: monitoring severe AATD and optimising treatment (2017) (0)
- Faculty Opinions recommendation of Development of a decision tree to assess the severity and prognosis of stable COPD. (2012) (0)
- Prescription of physical activity in chronic obstructive pulmonary disease… and beyond. (2017) (0)
- CAT in COPD phenotypes (POPE study) (2016) (0)
- BLOOD EOSINOPHILS AS A PREDICTIVE MARKER OF EXACERBATION RISK IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: RESULTS FROM A POOLED ANALYSIS OF 22,125 PATIENTS (2019) (0)
- Evaluation of nutritional status, disease severity and anxiety/depression in COPD patients with different exercise capacity (2016) (0)
- The effect of COVID-19 pandemics on the comprehensive laboratory diagnostic of alpha-1 antitrypsin deficiency in Europe - report from the AATD LABNet (2022) (0)
- [Delayed prescription of antibiotics. Also for COPD?]. (2006) (0)
- The burden of COPD in young individuals: results from EPISCAN II (2021) (0)
- Understanding the burden of chronic respiratory diseases : what decision makers need to know (2011) (0)
- COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients (2023) (0)
- [Inflammation, smoking and chronic obstructive pulmonary disease. Too many questions, few responses]. (2012) (0)
- COPD_A_310319 2149..2161 (2021) (0)
- Alpha-1 Antitrypsin Deficiency Laboratory Testing-External Quality Assessment Program AATD LABNet 2019-2021 (2022) (0)
- [Pneumologists: Where are we going and where have we come from?]. (2002) (0)
- Economic Impact of Low Adherence to COPD Management Guidelines in Spain (2021) (0)
- [Presentation. COPD]. (2010) (0)
- AB016. Characteristics of newly diagnosed COPD patients without maintenance treatment: a population-based study. (2016) (0)
- [Quality of life in patients with COPD: quantification criteria and therapeutic repercussions]. (2005) (0)
- ResearchColour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease (2010) (0)
- Infective exacerbations of COPD (2013) (0)
- Towards Optimum Reporting of Pulmonary Effectiveness Databases and Outcomes (TORPEDO): identifying a core dataset for asthma and COPD studies (2021) (0)
- Distribution of COPD phenotypes according to the Spanish COPD guidelines in clinical practice (2015) (0)
- Evolution of quality of life (CAT and CCQ) after a COPD exacerbation (2013) (0)
- Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East-North Africa region, 2017 [Corrigendum] (2019) (0)
- C URRENT OPINION Role of infection in exacerbations of chronic obstructive pulmonary disease (2015) (0)
- Disease Burden for Patients with Chronic Obstructive Pulmonary Disease Receiving Maintenance Therapy (2020) (0)
- Factors For Late Recovery (e8 Days) From Acute Exacerbation Of Chronic Bronchitis (2010) (0)
- HLA-DRB1 Alleles are Associated With COPD in a Latin American Admixed Population (0)
- University of Birmingham Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency (0)
- Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy (2022) (0)
- PRO60 Clinical and Economic Burden Associated with ALPHA-1 Antitrypsin Deficiency (AATD) in Adults: Systematic and Targeted Literature Reviews (2020) (0)
- The Spectrum of Bronchial Infection (2013) (0)
- Feasibility of a genotyping system for the diagnosis of alpha1 antitrypsin deficiency: a multinational cross-sectional analysis (2022) (0)
- Effectiveness and Safety of Inhaled Antibiotics in Patients With Chronic Obstructive Pulmonary Disease. A Multicentre Observational Study group on the effectiveness of inhaled antibiotic treatment in COPD” (2022) (0)
- Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research – a consensus document from six scientific societies [Corrigendum] (2019) (0)
- Structural and clinical characterization of novel missense variants of SERPINA1 gene causing alpha-1 antitrypsin deficiency (2019) (0)
- Discriminant Validity of a Single Clinical Question for the Screening of Inactivity in Individuals Living with COPD (2022) (0)
- Augmentation therapy for emphysema due to alpha-1 antitrypsin deficiency: Pro. (2018) (0)
- Lessons from large clinical trials in managing COPD patients (2009) (0)
- COPD_A_208245 1595..1601 (2019) (0)
- [Translated article] The ANTES Program in COPD: First Year. (2022) (0)
- Risk factors of poor outcomes after admission for a COPD exacerbations. Multivariate logistic predictive models (2015) (0)
- The effect of alpha-1 antitrypsin (AAT) augmentation therapy on the liver phenotype in individuals with homozygous Pi*Z AAT mutation (genotype Pi*ZZ) (2022) (0)
- Moxifl oxacin: a respiratory fl uoroquinolone (2008) (0)
- [The small, retracted, shrunk ... or timid lung?]. (1994) (0)
- Risk charts of five-year mortality in COPD patients (2019) (0)
- Longitudinal follow-up in adults with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype): non-invasive fibrosis tests predict liver-related endpoints (2022) (0)
- Phenotype-guided treatment of copd. Is it the future or the present? (2013) (0)
- Real-World Cost Effectiveness Comparison Of Symbicort Turbuhaler And Duoresp Spiromax In UK Patients With Asthma Or Chronic Obstructive Pulmonary Disease (2017) (0)
- COPD_A_240720 681..690 (2020) (0)
- COPD_A_265470 2683..2693 (2020) (0)
- [Profiles of cases included in the Spanish registry of patients with alpha-1 antitrypsin deficiency]. (2016) (0)
- COPD_A_312560 1783..1799 (2021) (0)
- The ANTES program in COPD: First year. (2021) (0)
- Subject Index, Vol. 61, 1994 (1994) (0)
- [Presentation. Asthma-like COPD]. (2010) (0)
- Respiratory symptoms and their determinants in the general Spanish population: changes over 20 years (2022) (0)
- Euro peanRespiratory News (2014) (0)
- COPD_A_357491 621..630 (2022) (0)
- Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry (2023) (0)
- Faculty Opinions recommendation of Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. (2010) (0)
- Inter-relationship of different types of respiratory symptoms in COPD (2014) (0)
- [Is it necessary to add a fourth drug to the initial treatment of tuberculosis?]. (2001) (0)
- cacy of amoxycillin versus amoxycillin / clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care (2008) (0)
- “ANTIBIOTICS FOR CHRONIC BRONCHITIS: A META-ANALYSIS THAT SPEAKS ONLY FOUR LANGUAGES”. M. MIRAVITLLES, B. CELLI AND A. ANZUETO. EUR RESPIR J 2007; 30: 815. (2007) (0)
- Late Breaking Abstract - Impact of COVID-19 on patients with severe alpha1 antitrypsin deficiency: the IMCA1 study of the EARCO ERS Clinical Research Collaboration, preliminary findings (2021) (0)
- Observational study to characterise 24-hour COPD symptoms: Interim analysis of ASSESS (2013) (0)
- Research priorities in alpha-1 antitrypsin deficiency (AATD) for healthcare professionals (2020) (0)
- [Should we administer replacement therapy to patients with alpha-1-antitrypsin deficit?]. (1998) (0)
- Faculty Opinions recommendation of Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. (2011) (0)
- Evaluation of respiratory symptoms in COPD patients from seven Latin America countries: The LASSYC Study (2017) (0)
- Periostin as a marker of Th2-related inflammation in patients with different types of chronic obstructive airway disease (2017) (0)
- Benefits of Tiotropium/Olodaterol Over Tiotropium Alone in Delaying Clinically Significant Deterioration in Patients with COPD (2020) (0)
- N95 Respirators or Surgical Masks to Protect Healthcare Workers against Respiratory Infections: Are We There Yet? (2013) (0)
- Expert Review of Respiratory Medicine , dedicated to the new questions and answers in COPD , provides an overview of five of the most frequent and relevant questions related to the management of patients with COPD . ” (2013) (0)
- Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? (2019) (0)
- Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine (2017) (0)
- PHARMACOKINETIC PROFILE OF ISONIAZID, RIFAMPIN AND PYRAZINAMIDE IN PATIENTS WITH TUBERCULOSIS. (1999) (0)
- Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum] (2019) (0)
- [Estimation of initial interobserver variability of forced spirometry in the multicenter epidemiological study IBERPOC. Scientific Committee of the IBERPOC study]. (1997) (0)
- Antibody response to H influenzae type b vaccine in patients with bronchiectasis (1997) (0)
- PRS9 CLINICAL PRACTICE VS GOLD RECOMMENDATIONS IN THE MANAGEMENT OF COPD PATIENTS: AN ECONOMIC ANALYSIS OF THE LACK OF ADHERENCE TO GUIDELINES (2006) (0)
- Chronic obstructive pulmonary disease: treatment (Part Two) (2006) (0)
- Impaired pulmonary and muscle function during moderate exercise in female patients recovered from SARS-CoV-2 (2022) (0)
- Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective (2019) (0)
- costs derived from the management of AECB and acute exacerbations of COPD , and to estimate the cost associated with relapse (2002) (0)
- Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD) (2021) (0)
- Screening of chronic liver disease by transient elastography in patients with lung disease associated with alpha-1 antitrypsin deficiency. (2018) (0)
- Rebuttal From Drs Barrecheguren and Miravitlles. (2018) (0)
- Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK (2017) (0)
- Antibiotic treatment for chest infections in the elderly. Why not consider chronic obstructive pulmonary disease (2018) (0)
- Baseline characteristics of patients enrolled in the EARCO prospective registry of alpha-1 antitrypsin deficiency: preliminary results (2021) (0)
- Chronic bronchial infection in stable COPD: To treat or not to treat. (2023) (0)
- [Travelling with oxygen. Thoughts on the first international meeting of patients with alpha 1-antitrypsin deficiency]. (2004) (0)
- PRS13 ECONOMIC IMPACT OF NON-ADHERENCE TO GOLD GUIDELINES IN COPD PATIENTS IN PRIMARY CARE IN SPAIN (2010) (0)
- Relationship Between Clinical Control, Respiratory Symptoms and Quality of Life for Patients with COPD (2020) (0)
- Bronchoalveolar Lavage-Induced Pneumomediastinum (1995) (0)
- COPD_A_207775 1267..1280 (2019) (0)
- Alpha-1 antitrypsin (AAT) augmentation therapy and liver phenotype in individuals with homozygous Pi*Z AAT mutation (Pi*ZZ genotype) (2022) (0)
- Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond (2022) (0)
- Routine blood test biomarkers and their association with exacerbations in COPD (2019) (0)
- Health-related quality of life in emphysema due to alpha-1-antitrypsin deficiency (2013) (0)
- Correction: Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study (2019) (0)
- Prevalence and incidence of bronchiectasis in Catalonia in 2012 (2016) (0)
- The clinical course of COPD: earlier intervention (2009) (0)
- Estimation of Generic Utilities in Spanish Chronic Obstructive Pulmonary Disease Patients (2013) (0)
- Faculty Opinions recommendation of Susceptibility to exacerbation in chronic obstructive pulmonary disease. (2010) (0)
- PRS11 - INITIATION OF TRIPLE THERAPY IN NEWLY DIAGNOSED COPD PATIENTS (2018) (0)
- Clinical and functional characteristics of Italian and Spanish patients with alpha 1-antitrypsin deficiency (2012) (0)
- Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey (2022) (0)
- Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Antitrypsin Genotype in Subjects With Chronic Obstructive Pulmonary Disease. (2023) (0)
- COPD_A_246571 921..929 (2020) (0)
- External quality assessment (EQA) for laboratory diagnosis of alpha1-antitrypsin deficiency (AATD) – Program driven by the European Alpha-1-Research Collaboration (EARCO) network (2021) (0)
- Respuesta de anticuerpos especificos contra la vacuna neumococica en una poblacion adulta sana y en enfermos con patologia pulmonar infecciosa (1997) (0)
- Enfermedad pulmonar obstructiva crónica (2003) (0)
- Identificación de miRNAs como biomarcadores moleculares del fenotipo mixto asma-EPOC (ACO) (2019) (0)
- 27 - Déficit de α 1 -antitripsina y otras causas de enfisema (2010) (0)
- EXPERT-ON, PRIMERA MONOGRAFÍA (2016) (0)
- Enfermedad Pulmonar Obstructiva (EPOC): Impacto y agudizaciones (2004) (0)
- Eficacia y tolerabilidad de budesonida/formoterol añadido a tiotropio en pacientes con enfermedad pulmonar obstructiva crónica (2009) (0)
- La formación especializada en neumología en Europa. El proyecto HERMES (2009) (0)
- colonisation in chronic obstructive pulmonary disease (2010) (0)
- Respuesta a: Martínez-Velilla N. Guía GesEPOC y pacientes ancianos (2014) (0)
- Prescripción de actividad física en la enfermedad pulmonar obstructiva crónica… y más allá (2017) (0)
- Guía Española de la EPOC (GesEPOC). Diagnóstico y tratamiento hospitalario de la agudización de la EPOC (2013) (0)
- Respirar a pleno pulmón: cómo prevenir los problemas respiratorios (1996) (0)
- In response to: Martínez-Velilla N. GesEPOC guidelines and elderly patients. (2014) (0)
- Características de los casos incluidos en el Registro Español de Pacientes con déficit de alfa-1 antitripsina (2016) (0)
- Prognostic factors for short and long term outcomes of outpatient exacerbations in moderate-to-severe COPD (2012) (0)
- TÜBERKÜLOZ ve TORAKS TUBERCULOSIS and THORAX (2011) (0)
- Preface (2015) (0)
- COPD_A_327803 2617..2630 (2021) (0)
- Visión evolutiva en el tratamiento de la enfermedad pulmonar obstructiva crónica (EPOC) (2017) (0)
- SEPAR ’ s voice Spanish COPD Guidelines ( GesEPOC ) 2017 . Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease (2019) (0)
- Niveles de proteína C reactiva en las exacerbaciones de la enfermedad pulmonar obstructiva crónica no grave (2013) (0)
- Foreword (2023) (0)
- Burden of disease among exacerbating patients with eosinophil COPD treated with triple therapy in Spain (2020) (0)
- Respuesta a: Martínez-Velilla N. Guía GesEPOC y pacientes ancianos (2014) (0)
- Bronchodilators are central to the management of stable chronic obstructive pulmonary disease in the elderly (2010) (0)
- Prescripción diferida de antibióticos. ¿También para la enfermedad pulmonar obstructiva crónica? (2006) (0)
- When to use and when not to use inhaled corticosteroids in COPD (2013) (0)
- Diagnosis of alpha 1 antitrypsin deficiency in primary care (2015) (0)
- VALIDATION OF AN ASSESSMENT TOOL FOR CONTROL IN COPD: ANALYSIS OF CLINICAL VARIABLES. (2018) (0)
- Evolution and Comparative Analysis of Hospitalizations in Spain Due to COPD and Bronchiectasis between 2004 and 2015 (2021) (0)
- Diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. (2001) (0)
- COPD_A_253567 1643..1654 (2020) (0)
- Inflamación, tabaco y enfermedad pulmonar obstructiva crónica. Demasiadas preguntas y pocas respuestas (2012) (0)
- Glycopyrronium: a new long-acting anticholinergic for maintenance treatment of COPD (2014) (0)
- The Capacity of Daily Living during the Morning (CDLM) questionnaire: Evaluating the impact of morning symptoms in COPD (2018) (0)
- Infección bronquial crónica en pacientes con EPOC (2014) (0)
- Don’t forget to walk at least 30 min per day 5 days a week. Why and how to prescribe physical exercise in chronic obstructive pulmonary disease (2015) (0)
- Antes: Un Año Despues En La Epoc (2021) (0)
- Uluslararasi Danişma Kurulu/International Advisory Board (2014) (0)
- Hay que añadir un cuarto fármaco a la pauta actual de tratamiento de la tuberculosis inicial (2001) (0)
- Guía Española de la EPOC Tratamiento farmacológico de la EPOC estable (2012) (0)
- Métodos diagnósticos neumológicos de la afectación pulmonar en pacientes con SIDA (1992) (0)
- Evidencias sobre la retirada de corticoides inhalados en la EPOC estable (2016) (0)
- Paradigmas en la enfermedad pulmonar obstructiva crónica (EPOC) y la doble broncodilatación con la combinación a dosis fijas de tiotropio + olodaterol (2017) (0)
- Vacuna antineumocócica: ¿la eterna incomprendida? (2000) (0)
- Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients (2019) (0)
- Patterns of initial treatment for COPD according to clinical phenotypes in Catalonia (2015) (0)
- [Translated article] Spanish COPD Guidelines (GesEPOC) 2021 Update. Diagnosis and Treatment of COPD Exacerbation Syndrome. (2022) (0)
- Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients (2021) (0)
- Artı́culo especial La formación especializada en neumologı́a en Europa . El proyecto HERMES (2009) (0)
- Use of Computed Tomography Lung Densitometry as an Outcome Measure for Emphysema Progression: The Case of Losartan (2022) (0)
- Impact of lung function impairment and exacerbation history on COPD patient-reported utility (2014) (0)
- Prevalence of reduced lung diffusing capacity and CT scan findings in smokers without airflow limitation: a population-based study (2023) (0)
- Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer (2022) (0)
- Optimal Treatment of the Symptomatic Smoker: Make a Diagnosis Not Empiric Treatment. (2022) (0)
- Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study [Corrigendum] (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Marc Miravitlles?
Marc Miravitlles is affiliated with the following schools:
